User menu

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.

Bibliographic reference Berlière, Martine ; Dalenc, Florence ; Malingret, Nathalie ; Vindevogel, Anita ; Piette, Philippe ; et. al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.. In: BMC Cancer, Vol. 8, no. 1, p. 56 (2008)
Permanent URL http://hdl.handle.net/2078.1/25221
  1. Bines J, Oleske D M, Cobleigh M A, Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer., 10.1200/jco.1996.14.5.1718
  2. Valagussa P, Moliterni A, Zambetti M, Bonadonna G: Long-term sequelae from adjuvant chemotherapy: recent results. Cancer Res. 1993, 127: 247-255.
  3. Meirow Dror, Reproduction post-chemotherapy in young cancer patients, 10.1016/s0303-7207(00)00365-8
  4. Vegetti Walter, Marozzi Anna, Manfredini Emanuela, Testa Giovanna, Alagna Federica, Nicolosi Annaelisa, Caliari Ilaria, Taborelli Monica, Tibiletti Maria Grazia, Dalprà Leda, Crosignani Pier Giorgio, Premature ovarian failure, 10.1016/s0303-7207(99)00224-5
  5. Padmanabhan N., Howell A., Rubens R.D., MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER, 10.1016/s0140-6736(86)92131-8
  6. Warne G. L., Fairley K. F., Hobbs J. B., Martin F. I. R., Cyclophosphamide-Induced Ovarian Failure, 10.1056/nejm197311292892202
  7. Goldhirsch A., Gelber R. D., Castiglione M., The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients, 10.1093/oxfordjournals.annonc.a057718
  8. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL: Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at MD Anderson Hospital and Tumor Institute. J Natl Cancer Inst Monogr. 1986, 1: 105-109.
  9. Levine M N, Bramwell V H, Pritchard K I, Norris B D, Shepherd L E, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams C K, Tu D, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group., 10.1200/jco.1998.16.8.2651
  10. Roché Henri, Fumoleau Pierre, Spielmann Marc, Canon Jean-Luc, Delozier Thierry, Serin Daniel, Symann Michel, Kerbrat Pierre, Soulié Patrick, Eichler Françoise, Viens Patrice, Monnier Alain, Vindevoghel Anita, Campone Mario, Goudier Marie-Josèphe, Bonneterre Jacques, Ferrero Jean-Marc, Martin Anne-Laure, Genève Jean, Asselain Bernard, Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, 10.1200/jco.2006.07.3916
  11. Fornier Monica N., Modi Shanu, Panageas Katherine S., Norton Larry, Hudis Clifford, Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane, 10.1002/cncr.21385
  12. Davis Amy L., Klitus Matthew, Mintzer David M., Chemotherapy-Induced Amenorrhea from Adjuvant Breast Cancer Treatment: The Effect of the Addition of Taxanes, 10.3816/cbc.2005.n.046
  13. Tham Yee-Lu, Sexton Krystal, Weiss Heidi, Elledge Richard, Friedman Lois C., Kramer Rita, The Rates of Chemotherapy-Induced Amenorrhea in Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Followed by a Taxane : , 10.1097/01.coc.0000251398.57630.4f
  14. Clemons Mark, Simmons Christine, Identifying menopause in breast cancer patients: considerations and implications, 10.1007/s10549-006-9401-y
  15. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Owell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C: TAC improves disease-free survival and overall survival over FAC in node-positive early breast cancer patients, BCIRG 001. SABCS. 2003, abstract no 43-
  16. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C, Riva A: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc Ann Meet Am Soc Clin Oncol. 2002, 141 (abstract)-
  17. Ferretti G., Chemotherapy-induced amenorrhea in early breast cancer, 10.1093/annonc/mdj011
  18. Abusief ME, Missmer SA, Ginsburg , Weeks JC, Wiener EP, Partridge AH: The effect of paclitaxel, dose density and trastuzumab in chemotherapy-related amenorrhea (CRA) in premenopausal women with breast cancer. San Antonio. 2006, Abstract 2079-
  19. Walshe Janice M., Denduluri Neelima, Swain Sandra M., Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer, 10.1200/jco.2006.07.2793
  20. Bonadonna Gianni, Valagussa Pinuccia, Moliterni Angela, Zambetti Milvia, Brambilla Cristina, Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up, 10.1056/nejm199504063321401
  21. Parulekar Wendy R., Day Andrew G., Ottaway Jon A., Shepherd Lois E., Trudeau Maureen E., Bramwell Vivien, Levine Mark, Pritchard Kathleen I., Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5, 10.1200/jco.2005.07.096
  22. Poikonen P, Saarto T, Elomaa I, Joensuu H, Blomqvist C, Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients, 10.1016/s0959-8049(99)00225-7
  23. Aebi Stefan, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?, 10.1016/s0140-6736(00)02292-3
  24. Del Mastro Lucia, Venturini Marco, Roberto Sertoli Mario, Rosso Riccardo, Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications, 10.1023/a:1005792830054
  25. Borde F, Chapelle-Marcilac I, Fumoleau P, Hery M, Roché H: Role of chemotherapy-induced amenorrhea in premenopausal node-positive operable breast cancer patients: 9-year follow-up results of French adjuvant study group. FASG data base. Breast Cancer Res Treat 2003. 1982, S30-
  26. Powles T.J., II.1 Tamoxifen's oestrogen-like effects in a breast cancer chemoprevention trial, 10.1016/s0959-8049(98)00090-2
  27. Brincker H, Rose C, Rank F, Mouridsen H T, Jakobsen A, Dombernowsky P, Panduro J, Andersen K W, Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer., 10.1200/jco.1987.5.11.1771
  28. Vanhuyse M, Fournier C, Bonneterre J: Chemotherapy-induced amenorrhea influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol. 2005, 1283-1288. 10.1093/annonc/mdi241.
  29. Pagani O., O’Neill A., Castiglione M., Gelber R.D., Goldhirsch A., Rudenstam C.-M., Lindtner J., Collins J., Crivellari D., Coates A., Cavalli F., Thürlimann B., Simoncini E., Fey M., Price K., Senn H.-J., Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI, 10.1016/s0959-8049(97)10036-3
  30. Cohen Ilan, Figer Arie, Tepper Ron, Shapira Jeremiah, Altaras Marco M., Yigael Dror, Beyth Yoram, Ovarian Overstimulation and Cystic Formation in Premenopausal Tamoxifen Exposure: Comparison between Tamoxifen-Treated and Nontreated Breast Cancer Patients, 10.1006/gyno.1998.5201
  31. Blumenfeld Zeev, Haim Nissim, Prevention of Gonadal Damage during Cytotoxic Therapy, 10.3109/07853899708999337
  32. Blumenfeld Z, Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers, 10.1016/s0303-7207(01)00712-2
  33. Rubens R.D., Knight R.K., Fentiman I.S., Howell A., Crowther D., George W.D., Hayward J.L., Bulbrook R.D., Chaudary M., Bush H., Sellwood R.A., Howat J.M.T., CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER, 10.1016/s0140-6736(83)91385-5